Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 matuzumab) in patients with recurrent cervical cancer

J. Blohmer, M. Gore, S. Kuemmel, RHM Verheijen, R. Kimmig, LFAG Massuger, A. du Bois, W.M Smit, D. Weber, C. Deubelbeiss

Research output: Contribution to conferenceAbstractOther research output

Original languageEnglish
Publication statusPublished - 2005
EventASCO - Orlando, United States
Duration: 13 May 200517 May 2005


Country/TerritoryUnited States

Cite this